Agency Will Request More Voluntary Safety Data Disclosure By Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
Controversy involving pediatric antidepressant use has encouraged FDA to accelerate public release of safety review data, Acting Deputy Commissioner for Policy Sachdev says. A planned partnership with CMS will also allow for better post-marketing safety surveillance.